Wyeth ( WYE) reported second-quarter earnings of $1.27 billion, or 94 cents a share, an increase from year-earlier earnings of $1.12 billion, or 83 cents a share, despite a 4% decline in revenue to $5.7 billion.

Excluding certain items, earnings in the latest period were 98 cents a share, above the expectation of analysts of 85 cents a share.

In a statement Thursday, the pharmaceuticals company said net revenue, excluding the impact of foreign exchange, rose by 2%. Sales of Prevnar rose 24%, while sales of Enbrel outside the U.S. and Canada gained 21%.

Wyeth raised its 2009 adjusted earnings guidance to $3.48 to $3.58 a share. Analysts polled by Thomson Reuters expect earnings of $3.46 a share.

Wyeth's merger with Pfizer ( PFE) is expected to close at the end of the third quarter or during the fourth quarter.

If you liked this article you might like

The Most Beloved Brands in America

CEOs Focus on Growth in 2010

CEOs Focus on Growth in 2010

A Peek at Jim Cramer's Portfolio

Glaxo, Wyeth Cut Costs With Trial Software

Glaxo, Wyeth Cut Costs With Trial Software

Biotech Stock Mailbag: Oncothyreon

Biotech Stock Mailbag: Oncothyreon